1. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995; 39:265–92.
Article
2. Sugiura S. Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 1978; 22:9–35.
Article
3. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science. 1978; 202:436–8.
Article
4. Sawady J, Mercer BM, Wapner RJ. . The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects of Antenatal Repeated Steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. Am J Obstet Gynecol. 2007; 197:281.e1–8.
Article
5. Rao NA, Sukavatcharin S, Tsai JH. Vogt-Koyanagi-Harada disease diagnostic criteria. Int Ophthalmol. 2007; 27(2-3):195–9.
Article
6. Nohara M, Norose K, Segawa K. Vogt-Koyanagi-Harada disease during pregnancy. Br J Ophthalmol. 1995; 79:94–5.
Article
7. MacLean MA, Wilson R, Thomson JA. . Changes in immunologic parameters in normal pregnancy and spontaneous abortion. Am J Obstet Gynecol. 1991; 165(4 Pt 1):890–5.
Article
8. Satoh A, Koh M, Tamura H. Harada's disease in pregnancy, a case report. Folia Ophthalmol Jpn. 1986; 37:460–5.
9. Sato S, Kou M, Tamaru H. Incomplete type Harada's disease in early pregnant stage treated with topical corticosteroid. Nippon Ganka Kiyu (Folia Ophthalmol Jpn). 1986; 37:46–50.
10. Taguchi C, Ikeda E, Hikita N, Mochizuki M. [A report oftwo cases suggesting positive influence of pregnancy on uveitis activity]. Nihon Ganka Gakkai Zasshi. 1999; 103:66–71.
11. Miyata N, Sugita M, Nakamura S. . Treatment of Vogt- Koyanagi-Harada's disease during pregnancy. Jpn J Ophthalmol. 2001; 45:177–80.
12. Reed L HM, Shlomo M, Keneth Sp. Williams text book of endocrinology. 10th ed.Philadelphia: Saunders;2003.
13. Friedman Z, Granat M, Neumann E. The syndrome of Vogt- Koyanagi-Harada and pregnancy. Metab Pediatr Ophthalmol. 1980; 4:147–9.
14. Wittig EO, Moreira CA, Basedow H. [Vogt-Koyanagi syndrome. Report of a case in a pregnant woman]. Arq Neuropsiquiatr. 1983; 41:385–90.
15. Steahly LP. Vogt-Koyanagi-Harada syndrome and pregnancy. Ann Ophthalmol. 1990; 22:59–62.
16. Dombrowski MP, Brown CL, Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. J Matern Fetal Med. 1996; 5:310–3.
Article
17. Degenring RF, Jonas JB. Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004; 137:1142–3.
Article
18. Byon IS, Kim JH, Lee JE, Oum BS. Intravitreal triamcinolone ace- tonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease. Clin Ophthalmol. 2011; 5:1589–91.
19. Andrade RE, Muccioli C, Farah ME. . Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2004; 137:572–4.
Article